NervGen Pharma's NVG-291-R Demonstrates Significant Functional Recovery in Department of Defense-Sponsored Preclinical Models of Traumatic Hearing Loss and Peripheral Nerve Injury
Vancouver, British Columbia--(Newsfile Corp. - August 21, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biopha
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-08-21 7:30 AM EDT | NervGen Pharma Corp.
Republic Technologies Announces 2025 AGSM Results
Vancouver, British Columbia--(Newsfile Corp. - August 20, 2025) - Republic Technologies Inc. (CSE: DOCT) (FSE: 7FM0) (the "Company" or "Republic") is pleased to announce that all matters put forth at the Company's Annual General and Special Meeting of Shareholders (the "Meeting") held on August 19, 2025 were approved by its shareholders. The Company's shareholders voted to fix the number of directors of the Company at four and elected the following four nomi
Technology, Pharmaceuticals, Health
2025-08-20 8:32 PM EDT | Republic Technologies Inc.
Hemostemix's Social Media for Investors and Florida's No-Option Patients
Calgary, Alberta--(Newsfile Corp. - August 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering treatments for no-option patients in Florida suffering from Chronic Limb Threatening Ischemia, Peripheral Arterial Disease, Angina, Ischemic Cardiomyopathy, non Ischemic Dilated Cardiomyopathy, and Congestive Heart Failure, is pleased to announce additions to its investor awareness and social media strat
Biotechnology, Pharmaceuticals, Health
2025-08-20 7:35 AM EDT | Hemostemix Inc.
Optimi Health Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - August 20, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a manufacturer of GMP-certified MDMA and psilocybin, is pleased to announce it has entered into an agreement with MZ Investor Relations ("MZ"), an investor relations firm. MZ will provide Optimi with strategic support in capital markets advisory, corporate communications, and investor engagement. Under the te
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-08-20 7:30 AM EDT | Optimi Health Corp.
BioGene Therapeutics Inc. Appoints Dr. Francis Tavares, PhD., as Chief Technology Officer
Vancouver, British Columbia--(Newsfile Corp. - August 20, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed of Dr. Francis Tavares as Chief Technology Officer effective on 19 August,
Biotechnology, Pharmaceuticals, Health
2025-08-20 7:00 AM EDT | PreveCeutical Medical Inc.
Bachem Expands Corporate Executive Committee to Include Chief Operations Officer Role
Bubendorf, Switzerland--(Newsfile Corp. - August 20, 2025) - The Bachem Group (SIX: BANB) announced today that Hans Van Hees, currently Chief Operations Officer Europe, will take on the role of Chief Operations Officer (COO) and join the Corporate Executive Committee (CEC) as of September 1, 2025. In this role, he will report to the CEO of Bachem, Thomas Meier, and will lead Bachem’s worldwide manufacturing network. Thomas Meier, who, in addition to his role as CEO, had
Biotechnology, Chemical, Healthcare and Hospitals, Pharmaceuticals
2025-08-20 1:08 AM EDT | Bachem Holding AG
Custom Health Acquires PatchRx to Expand Patient Connected Care Platform
British Columbia and New York, New York--(Newsfile Corp. - August 19, 2025) - Custom Health, Inc., a vertically integrated, tech-enabled care platform, announces the acquisition of PatchRx, Inc., a medication adherence and remote monitoring technology company. This transaction advances Custom Health's outcomes-driven medication programs by enabling prescription medication dispensing with real-time insights to improve care for patients managing chronic conditions while lowering health
Technology, Pharmaceuticals, Health
2025-08-19 8:00 AM EDT | Custom Health
BioGene Therapeutics Inc. Appoints Dr. Kamal Albarazanji as Senior Director of Metabolic Research
Vancouver, British Columbia--(Newsfile Corp. - August 19, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed Dr. Kamal Albarazanji as Senior Director of Metabolic Research effective on
Biotechnology, Pharmaceuticals, Health
2025-08-19 7:00 AM EDT | PreveCeutical Medical Inc.
Hemostemix Announces Its AI Strategy
Calgary, Alberta--(Newsfile Corp. - August 19, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own) stem cell therapy company treating no-option patients in Florida suffering in pain from Chronic Limb Threatening Ischemia, Peripheral Arterial Disease and Angina, is pleased to announce its webinar topic for Thursday, August 21, 2025. Croom Lawrence, Chief Commercialization Officer, Hemostemix, who completed exec
Biotechnology, Pharmaceuticals, Health
2025-08-19 6:54 AM EDT | Hemostemix Inc.
Maxwell Biosciences Marks Scientist Appreciation Day With Renewed Call to Recognize Scientists
Austin, Texas--(Newsfile Corp. - August 18, 2025) - Maxwell Biosciences, a global health technology company pioneering a new category of immune-inspired small molecules called Claromers™, today celebrates Scientist Appreciation Day, an official company holiday that honors the essential contributions of scientists. The observance is a call to give scientists greater visibility and broader recognition of their work at a time when scientific research faces growing challenges in visibility
Biotechnology, Pharmaceuticals
2025-08-18 9:00 AM EDT | Maxwell Biosciences, Inc.
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2026 ended June 30, 2025 and Provides Conference Call Information
Northvale, New Jersey--(Newsfile Corp. - August 14, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the first quarter of fiscal year 2026 ended June 30, 2025 ("First Quarter"). Consolidated revenues for the three-month period ending June 30, 2025, were $40.2 million, an increase of $21.4 million or approximately 114% as compared to the comparable period of
Healthcare and Hospitals, Pharmaceuticals, Health
2025-08-14 4:24 PM EDT | Elite Pharmaceuticals, Inc.
Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
King of Prussia, Pennsylvania--(Newsfile Corp. - August 14, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-08-14 4:15 PM EDT | Phio Pharmaceuticals Corp.
Hemostemix's Expands its Marketing Team Focused on Sales in Florida
Calgary, Alberta--(Newsfile Corp. - August 14, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), an autologous stem cell company developing and commercializing VesCell™ (ACP-01), announces the appointment of a seasoned commercial team encompassing marketing, sales, e-commerce and patient care communications, in compliance with federal and state regulations. The appointments enable Hemostemix to sell VesCell™ in Florida to podiatrist and vascular surgeons, to treat P
Biotechnology, Pharmaceuticals, Health
2025-08-14 9:17 AM EDT | Hemostemix Inc.
Entero Therapeutics, Inc. Announces Reverse Stock Split
Boca Raton, Florida--(Newsfile Corp. - August 14, 2025) - Entero Therapeutics, Inc. (NASDAQ: ENTO) (the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced that, it will effect a 1 for 3 reverse stock split of its common stock. The Company expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on A
Biotechnology, Pharmaceuticals
2025-08-14 9:15 AM EDT | Entero Therapeutics, Inc.
PharmaTher Founder and CEO Issues Letter to Shareholders Following the FDA Approval of Ketamine (KETARx(TM))
Toronto, Ontario--(Newsfile Corp. - August 14, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, announced today that Fabio Chianelli, the Company's Founder, Chairman and Chief Executive Officer, has issued the following letter to shareholders. Dear Fellow Shareholders, Earlier this year, I wrote to you about the challenges we faced with our
Biotechnology, Pharmaceuticals
2025-08-14 8:00 AM EDT | PharmaTher Holdings Ltd.
Neural Announces Completion of the Acquisition of a 30.75% Interest in Hanf.com, a Profitable German CBD Retail Store Chain
Toronto, Ontario--(Newsfile Corp. - August 13, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-08-13 7:30 AM EDT | Neural Therapeutics Inc.
Medexus Announces Fiscal Q1 2026 Results, Including Positive Results from US Launch of GRAFAPEX (treosulfan) for Injection
Fiscal Q1 2026 net revenue of $24.6 million, net income of $0.5 million, operating income of $0.9 million, and Adjusted EBITDA* of $3.4 million $3.0 million of product-level net revenue from GRAFAPEX in fiscal Q1 2026, relative to $3.0 million of personnel and infrastructure investments, further supporting Medexus's confidence in the product's potential Management to host conferenc
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-08-12 5:30 PM EDT | Medexus Pharmaceuticals Inc.
Oh Digital Diary Revives 2020-Born Royaluxe & Co as a Global Luxury Powerhouse
Tlemcen, Algeria--(Newsfile Corp. - August 12, 2025) - Oh Digital Diary, the Algerian luxury platform known for blending Arabesque elegance with a cosmopolitan vision, has announced a bold repositioning of Royaluxe & Co, a brand originally founded in 2020 by the same creator, Kaouter Nedjlaa Kibou. This strategic move transforms Royaluxe & Co into a multi-faceted luxury umbrella designed to extend Oh Digital
Internet Technology, Pharmaceuticals, Publishing / Informational Services, Health
2025-08-12 10:14 AM EDT | BrandingEx Solutions Pvt Ltd.
Hemostemix Contracts Empire Market Ventures to Increase Market Awareness
Calgary, Alberta--(Newsfile Corp. - August 12, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it contracted Empire Market Ventures to provide an investor market awareness program. Empire Market Ventures (EMV) is a premier consulting firm and full-service advertising and investor awareness agency based in New York City. Specializing in strategic communications, digital media, and market intelligence, EMV delivers tailored solutions that enhance the visibility
Biotechnology, Pharmaceuticals, Health
2025-08-12 10:01 AM EDT | Hemostemix Inc.
Quantum BioPharma Announces Update to Previously Announced Private Placement
Toronto, Ontario--(Newsfile Corp. - August 11, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that further to its press release dated June 27, 2025, the Company will be seeking shareholder approval of its non-brokered private placement of class A multiple voting shares ("MVS") for aggregate gross
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-08-11 6:32 PM EDT | Quantum BioPharma Ltd.